Purpose, strategy and culture

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

We aim to positively impact the health of 2.5 billion people by the end of the of decade, as a successful, growing company where people can thrive.

Our strategy

We are a focused biopharma company. We prevent and treat disease with vaccines, specialty and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/immunology and oncology). Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems.

Explore more on our global website below.

Our R&D approach

Partner with GSK

Our portfolio

Learn about our product portfolio and how we’re prioritizing vaccines and specialty medicines to get ahead of disease together.

Our Products

How we help people thrive

At GSK, culture is something we all own. It’s powered by the little things GSK people do every day to help us get ahead of disease together. It drives delivery of our strategy and makes GSK a place where people can thrive. Being ambitious for patients, accountable for impact and making sure we always do the right thing is how we deliver for patients, shareholders, and of course the people who work here. 

​​Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.

Our US business areas

Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. GSK is a company where outstanding people can thrive.

We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccine and medicines development.

Our long-term priorities